More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale ...

Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Ianalumab, which has already succeeded in testing against Sjogren’s syndrome, proved impactful in a condition that causes low ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...

Ianalumab acts against B cells, white blood cells in the immune system, when they overreact and mistakenly attack the patient's own body. By blocking signals that these B cells need to grow and ...

Ouro Medicines’ BCMAxCD3 T cell engager antibody candidate, gamgertamig gets US FDA orphan drug designation to treat immune thrombocytopenia: South San Francisco Tuesday, Decemb ...

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a ...

Clinicians who suspect their patients may have immune thrombocytopenia (ITP) should look for platelet autoantibodies both in the bloodstream and the bone marrow, new research suggests. "Diagnosing ITP ...

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...